Antiadhesion therapy for urinary tract infections-A balanced PK/PD profile proved to be key for success

Journal of Medicinal Chemistry

Volumn 55, Issue 10, 2012, Pages 4700-4713

  Jiang, Xiaohua ^a   Abgottspon, Daniela ^a   Kleeb, Simon ^a   Rabbani, Said ^a   Scharenberg, Meike ^a   Wittwer, Matthias ^a   Haug, Martina ^a   Schwardt, Oliver ^a   Ernst, Beat ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 (5 NITROINDOL 1 YL)PHENYL ALPHA DEXTRO MANNOPYRANOSIDE; 2 CHLORO 4 (5 NITROINDOLIN 1 YL)PHENYL 2,3,4,6 TETRA O ACETYL ALPHA DEXTRO MANNOPYRANOSIDE; 2 CHLORO 4 (5 NITROINDOLIN 1 YL)PHENYL ALPHA DEXTRO MANNOPYRANOSIDE; 2 CHLORO 4 (INDOL 1 YL)PHENYL ALPHA DEXTRO MANNOPYRANOSIDE; 4 (5 NITROINDOLIN 1 YL)PHENYL 2,3,4,6 TETRA O ACETYL ALPHA DEXTRO MANNOPYRANOSIDE; 4 (5 NITROINDOLIN 1 YL)PHENYL ALPHA DEXTRO MANNOPYRANOSIDE; ANTIINFECTIVE AGENT; CIPROFLOXACIN; FIMH PROTEIN; FIMH PROTEIN ANTAGONIST; INDOLINYLPHENYL MANNOSIDE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIUM ADHERENCE; BINDING AFFINITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG SOLUBILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; LIPOPHILICITY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROTEIN TARGETING; SINGLE DRUG DOSE; THERMODYNAMICS; URINARY TRACT INFECTION;

ADHESINS, ESCHERICHIA COLI; ANIMALS; ANTI-INFECTIVE AGENTS, URINARY; BACTERIAL ADHESION; BENZENE DERIVATIVES; CELL LINE; ESCHERICHIA COLI INFECTIONS; FIMBRIAE PROTEINS; INDOLES; KIDNEY; MANNOSIDES; MICE; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY BLADDER; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI; UROTHELIUM; VIRULENCE FACTORS;

EID: 84861499906     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300192x     Document Type: Article

References (56)

1. Berglund, J.; Knight, S. D. Structural basis for bacterial adhesion in the urinary tract Adv. Exp. Med. Biol. 2003, 535, 33-52
2. Westerlund-Wikström, B.; Korhonen, T. K. Molecular structure of adhesin domains in Escherichia coli fimbriae Int. J. Med. Microbiol. 2005, 295, 479-486 (Pubitemid 41225459)
3. Wiles, T. J.; Kulesus, R. R.; Mulvey, M. A. Origins and virulence mechanisms of uropathogenic Escherichia coli Exp. Mol. Pathol. 2008, 85, 11-19
4. Mulvey, M. A. Adhesion and entry of uropathogenic Escherichia coli Cell Microbiol. 2002, 4, 257-271 (Pubitemid 34567594)
5. Capitani, G.; Eidam, O.; Glockshuber, R.; Grutter, M. G. Structural and functional insights into the assembly of type 1 pili from Escherichia coli Microbes Infect. 2006, 8, 2284-2290 (Pubitemid 44311597)
6. Sharon, N. Carbohydrates as future anti-adhesin drugs for infectious diseases Biochim. Biophys. Acta 2006, 1760, 527-537
7. Firon, N.; Ofek, I.; Sharon, N. Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli Biochem. Biophys. Res. Commun. 1982, 105, 1426-1432 (Pubitemid 13222588)
8. Firon, N.; Ofek, I.; Sharon, N. Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae and Salmonella typhimurium Carbohydr. Res. 1983, 120, 235-249
9. Sharon, N. Bacterial lectins, cell-cell recognition and infectious disease FEBS Lett. 1987, 217, 145-157 (Pubitemid 17086739)
10. Pieters, R. J. Maximising multivalency effects in protein-carbohydrate interactions Org. Biomol. Chem. 2009, 7, 2013-2025
11. Imberty, A.; Chabre, Y. M.; Roy, R. Glycomimetics and glycodendrimers as high affinity microbial anti-adhesins Chem.-Eur. J. 2008, 14, 7490-7499
12. Hartmann, M.; Lindhorst, T. K. The bacterial lectin FimH, a target for drug discovery-carbohydrate inhibitors of type 1 fimbriae-mediated bacterial adhesin Eur. J. Org. Chem. 2011, 3583-3609
13. Choudhury, D.; Thompson, A.; Stojanoff, V.; Langermann, S.; Pinkner, J.; Hultgren, S. J.; Knight, S. D. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli Science 1999, 285, 1061-1066
14. Bouckaert, J.; Berglund, J.; Schembri, M.; Genst, E. D.; Cools, L.; Wuhrer, M.; Hung, C. S.; Pinkner, J.; Slättergard, R.; Zavialov, A.; Choudhury, D.; Langermann, S.; Hultgren, S. J.; Wyns, L.; Klemm, P.; Oscarson, S.; Knight, S. D.; Greve, H. D. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin Mol. Microbiol. 2005, 55, 441-455 (Pubitemid 40179379)
15. Wellens, A.; Garofalo, C.; Nguyen, H.; Van Gerven, N.; Slättergârd, R.; Hernalsteens, J.-P.; Wyns, L.; Oscarson, S.; De Greve, H.; Hultgren, S.; Bouckaert, J. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex PLos One 2008, 3, 4-13
16. Han, Z.; Pinker, J. S.; Ford, B.; Obermann, R.; Nolan, W.; Wildman, S. A.; Hobbs, D.; Ellenberger, T.; Cusumano, C. K.; Hultgren, S. J.; Janetka, J. W. Structure-based drug design and optimization of mannoside bacterial FimH antagonists J. Med. Chem. 2010, 53, 4779-4792
17. Sperling, O.; Fuchs, A.; Lindhorst, T. K. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands Org. Biomol. Chem. 2006, 4, 3913-3922 (Pubitemid 44600663)
18. Grabosch, C.; Hartmann, M.; Schmidt-Lassen, J.; Lindhorst, T. K. Squaric acid monoamide mannosides as ligands for the bacterial lectin FimH: Covalent inhibition or not? ChemBioChem 2011, 12, 1066-1074
19. Klein, T.; Abgottspon, D.; Wittwer, M.; Rabbani, S.; Herold, J.; Jiang, X.; Kleeb, S.; Lüthi, C.; Scharenberg, M.; Bezençon, J.; Gubler, E.; Pang, L.; Smiesko, M.; Cutting, B.; Schwardt, O.; Ernst, B. FimH antagonist for the oral treatment of urinary tract infections: From design and synthesis to in vitro and in vivo evaluation J. Med. Chem. 2010, 53, 8627-8641
20. Rabbani, S.; Jiang, X.; Schwardt, O.; Ernst, B. Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay Anal. Biochem. 2010, 407, 188-195
21. Cusumano, C. K.; Pinkner, J. S.; Han, Z.; Greene, S. E.; Ford, B. A.; Crowley, J. R.; Henderson, J. P.; Janetka, J. W.; Hultgren, S. J. Treatment and prevention of urinary tract infection with orally active FimH inhibitors Sci. Transl. Med. 2011, 3, 1-10
22. Kerékgyártó, J.; Kamerling, J. P.; Bouwstra, J. B.; Vliegenthasrt, J. F. G.; Liptak, A. Synthesis of four structural elements of xylose-containing carbohydrate chains from N-glycoproteins Carbohydr. Res. 1989, 186, 51-62
23. Ma, D.; Cai, Q. L-Proline promoted Ullmann type coupling reactions of aryl iodides with indoles, pyrroles, imidazoles or pyrazoles Synlett 2004, 128-130 (Pubitemid 38067810)
24. Ma, D.; Cai, Q. Copper/Amino acid catalyzed cross-couplings of aryl and vinyl halides with nucleophiles Acc. Chem. Res. 2008, 41, 1450-1460
25. Ley, S. V.; Thomas, A. W. Modern Synthetic methods for copper-mediated C(aryl)-O, C(aryl)-N, and C(aryl)-S bond formation Angew. Chem., Int. Ed. 2003, 42, 5400-5449 (Pubitemid 37466273)
26. Antilla, J. C.; Klapars, A.; Buchwald, S. L. The copper-catalyzed N-arylation of indoles J. Am. Chem. Soc. 2002, 124, 11684-11688
27. Kosak, J. R. Catalytic hydrogenation of aromatic halonitro compounds Ann. N.Y. Acad. Sci. 1970, 172, 175-185
28. Wolfe, J. P.; Wagaw, S.; Marcoux, J.-F.; Buchwald, S. L. Rational development of practical catalysts for aromatic carbon-nitrogen bond formation Acc. Chem. Res. 1998, 31, 805-818 (Pubitemid 128473631)
29. Prieto, M; Zurita, E.; Rosa, E.; Muñoz, L.; Lloyd-Williams, P.; Giralt, E. Arylboronic acids and arylpinacolboronate esters in Suzuki-coupling reactions involving indoles. Partner role swapping and heterocycle protection J. Org. Chem. 2004, 69, 6812-6820 (Pubitemid 39304815)
30. Abgottspon, D.; Rölli, G.; Hosch, L.; Steinhuber, A.; Jiang, X.; Schwardt, O.; Cutting, B.; Smiesko, M.; Jenal, U.; Ernst, B.; Trampuz, A. Development of an aggregation assay to screen FimH antagonists J. Microbiol. Methods 2010, 82, 249-255
31. Bouckaert, J.; Mackenzie, J.; de Paz, J. L.; Chipwaza, B.; Choudhury, D.; Zavialov, A.; Mannerstedt, K.; Anderson, J.; Pierard, D.; Wyns, L.; Seeberger, P. H.; Oscarson, S.; De Greve, H.; Knight, S. D. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes Mol. Microbiol. 2006, 61, 1556-1568 (Pubitemid 44359383)
32. Giampapa, C. S.; Abraham, S. N.; Chiang, T. M.; Beachey, E. H. Isolation and characterization of a receptor for type 1 fimbriae of Escherichia coli from guinea pig erythrocytes J. Biol. Chem. 1988, 263, 5362-5367
33. Aprikian, P.; Tchesnokova, V.; Kidd, B.; Yakovenko, O.; Yarov-Yarovoy, V.; Trinchina, E.; Vogel, V.; Thomas, W.; Sokurenko, E. Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose J. Biol. Chem. 2007, 282, 23437-23446 (Pubitemid 47311921)
34. Trong, I. L.; Aprikian, P.; Kidd, B. A.; Forero-Shelton, M.; Tchesnokova, V.; Rajagopal, P.; Rodriguez, V.; Interlandi, G.; Klevit, R.; Vogel, V.; Stenkamp, R. E.; Sokurenko, E. V.; Thomas, W. E. Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting Cell 2010, 141, 645-655
35. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 1998, 41, 1007-1010 (Pubitemid 28207375)
36. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. Parallel artificial membrane permeability assay (PAMPA)-critical factors for better predictions of absorption J. Pharm. Sci. 2007, 96, 2893-2909
37. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249 (Pubitemid 32239479)
38. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
39. van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics J. Med. Chem. 2001, 44, 1313-1333 (Pubitemid 32852106)
40. Schmidt, S.; Gonzalez, D.; Derendorf, H. Significance of protein binding in pharmacokinetics and pharmacodynamics J. Pharm. Sci. 2010, 99, 1107-1122
41. Trainor, G. L. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 2, 51-64 (Pubitemid 47078697)
42. Weisiger, R. A. Dissociation from albumin: a potentially rate-limiting step in the clearance of substances by the liver Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 1563-1567 (Pubitemid 15120585)
43. Dearden, J. C.; Bresnen, J. G. M. The measurement of partition coefficients QSAR Comb. Sci. 1988, 7, 133-144
44. Kerns, E. H. High throughput physicochemical profiling for drug discovery J. Pharm. Sci. 2001, 90, 1838-1858 (Pubitemid 33062605)
45. Banker, M. J.; Clark, T. H.; Williams, J. A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding J. Pharm. Sci. 2003, 92, 967-974 (Pubitemid 36523442)
46. Andrews, J. M. Determination of minimum inhibitory concentrations J. Antimicrob. Chemother. 2001, 48 (Suppl 1) 5-16
47. Scharenberg, M.; Abgottspon, D.; Ciceck, E.; Jiang, X.; Schwardt, O.; Rabbani, S.; Ernst, B. Flow cytometry-based assay for screening FimH antagonists Assay Drug Dev. Technol. 2011, 9, 455-464
48. Hooton, T. M. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection Int. J. Antimicrob. Agents 2003, 22, 65-72
49. Jakobsen, L.; Cattoir, V.; Hammerum, A. M.; Nordmann, P.; Frimodt-Møller, N. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19, and qnrS1 on ciprofloxacin treatment of Escherichia coli urinary tract infection in murine model. Poster presented at ICAAC 2010. 50th Interscience Conference on Antimicrobial Agents and Chemotharapy, 2010, Sep 12-15, Boston, MA.
50. Russell, W. M. S.; Burch, R. L. The Principles of Humane Experimental Technique; Methuen: London, 1959; reprinted: Universities Federation for Animal Welfare, Wheathampstead, United Kingdom, 1992.
51. Demers, G.; Griffin, G.; De Vroey, G.; Haywood, J. R.; Zurlo, J.; Bédard, M. Harmonization of animal care and use guidance Science 2006, 312, 700-701
52. Schwardt, O.; Rabbani, S.; Hartmann, M.; Abgottspon, D.; Wittwer, M.; Kleeb, S.; Zalewski, A.; Smiesko, M.; Cutting, B.; Ernst, B. Design, Synthesis and biological evaluation of mannosyl triazoles as FimH antagonists Bioorg. Med. Chem. 2011, 19, 6454-6473
53. Mulvey, M. A.; Schilling, J. D.; Hultgren, S. J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection Infect. Immun. 2001, 69, 4572-4579 (Pubitemid 32574459)
54. VCCLAB, Virtual Computational Chemistry Laboratory; http://www.vcclab. org, 2005.
55. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual computational chemistry laboratory-Design and description J. Comput.-Aided Mol. Des. 2005, 19, 453-463 (Pubitemid 41613292)
56. Kerrn, M. B.; Frimodt-Møller, N.; Espersen, F. Effects of sulfomethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection model Antimicrob. Agents Chemother. 2003, 47, 1002-1009 (Pubitemid 36254227)